Accent Therapeutics
Lexington, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $75M
Overview
Pioneering small molecule drugs that target RNA-modifying proteins to treat cancer with precision.
Oncology
Technology Platform
An integrated discovery platform that identifies and validates cancer-driving RNA-modifying proteins (RMPs) and develops selective small molecule inhibitors against them.
Funding History
1Total raised:$75M
Series C$75M
Opportunities
Potential to unlock a new universe of oncology targets with first-in-class medicines for patients resistant to current therapies.
Risk Factors
High biological risk associated with pioneering a novel target class, with potential for unforeseen on-target toxicities due to the fundamental role of RMPs in normal cells.
Competitive Landscape
A pioneer in the emerging field of epitranscriptomic drug discovery, with limited direct competition but facing the general high risk of novel target validation.